Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 0.79 |
| ▸ | TACR2 | P21452 | 6/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | TACR1 | P25103 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pavinetant SCHEMBL17132260 | 0.88 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Pavinetant SCHEMBL29375128 | 0.88 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Pavinetant SCHEMBL3587478 | 0.88 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3576483 | 0.85 | TACR3 (0.70) | TACR3CYP2C9 | |
| SCHEMBL3576487 | 0.85 | TACR3 (0.70) | TACR3CYP2C9 | |
| SCHEMBL18407125 | 0.84 | TACR3 (0.80) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4967130 | 0.83 | TACR3 (0.71) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4988147 | 0.83 | TACR3 (0.71) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4472989 | 0.82 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4472992 | 0.82 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071621-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071621-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071621-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-20100029717-A1 | Alkylsulphonamide Quinolines | SIMPSON THOMAS | 2010-02-04 | — | — | US | disclosed |
| US-20100029717-A1 | Alkylsulphonamide Quinolines | SIMPSON THOMAS | 2010-02-04 | — | — | US | disclosed |
| US-20100029717-A1 | Alkylsulphonamide Quinolines | SIMPSON THOMAS | 2010-02-04 | — | — | US | disclosed |
| US-7608628-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-7608628-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-7608628-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080021062-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| WO-2007069977-A1 | ALKYLSULPHONAMIDE QUINOLINES | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021062-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TACR3 1038/4885TACR2 730/4885CYP1A2 73/4885 |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, QDPR | TACR3 673/4885TACR2 581/4885CYP1A2 170/4885 |
| US-20100029717-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, QDPR | TACR3 673/4885TACR2 581/4885CYP1A2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.